End point Valsartan, n (%) Placebo, n (%) Hazard ratio (95% CI) P*

Slides:

Advertisements

Similar presentations

MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.

Advertisements

חזק בהגנה לבבית Valsartan in Heart Failure

Vasodilating Beta Blockers The New Frontier Abdul H Sankari, MD FACC FCCP.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

Randomized, double-blind, multicenter, controlled trial.

European Society of Cardiology Cardiovascular diseases in women.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Update on Valsartan Špinar J.. System renin-angiotensin-aldosteron angiotensinogen angiotensin I angiotensin II aldosteron ANP,BNP thirst resorp. Na +

BluntPenetrating Placebo rFVIIa Patients (%) n=20 n=8 n=9 n=4 P=0.03 P=0.068 Adapted from Rizoli S. Canadian Anesthesiologists’

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.

ISIS-4: Fourth International Study of Infarct Survival Purpose To assess the separate and combined effects on all-cause mortality of adding early captopril,

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Chemical Structure of Rosuvastatin Relative lipophilicity * Rosuvastatin Cerivastatin Simvastatin Fluvastatin Atorvastatin Pravastatin.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

SS-1 Candesartan Support Slides. SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Figure 1 Patient flow chart.

LEADER trial: Primary Outcome

Copyright © 2006 American Medical Association. All rights reserved.

Figure 1 Study flow chart

Beyond Current Strategies: Focus on Angiotensin Receptors

Valsartan in Acute Myocardial Infarction Trial Investigators

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Baseline characteristics of patients

End point Elevated PTH Normal PTH p % diameter stenosis < 0.05

Mean eGFR among survivors after CABG surgery vs all-cause deaths

Is Aprotinin Safe to Use in a Cohort at Increased Risk for Thrombotic Events: Results From a Randomized, Prospective Trial in Off-Pump Coronary Artery.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Association between highest tertile for homocysteine and mortality

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

CREATE: Baseline values

Todd C. Crawford, MD, J. Trent Magruder, MD, Joshua C

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

4D trial: Primary end point

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

VALUE: New-onset diabetes in an amlodipine-based vs valsartan-based therapy in high-risk hypertensives Diagnostic criteria Valsartan n (%) Amlodipine n.

Kimberley J. Hansen, MD, Gregory S. Cherr, MD, Timothy E

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Mintu P. Turakhia et al. JACEP 2016;2:

Svend A. Mortensen et al. JCHF 2014;2:

Volume 76, Issue 6, Pages (September 2009)

Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

E. Tacconelli Clinical Microbiology and Infection

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

Jordan B. King et al. JCHF 2016;4:

Michael R. Lattanzio, Matthew R. Weir Kidney International

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Pamela E. Scott et al. JACC 2018;71:

Welcome to the 6th ERAS World Congress Enhanced recovery after surgery Stockholm, Sweden.

Jeffrey Senfield et al. JACEP 2017;3:

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Presentation transcript:

Val-HeFT: Valsartan vs placebo in patients with and without renal dysfunction End point Valsartan, n (%) Placebo, n (%) Hazard ratio (95% CI) P* Death 0.57 GFR >60 132 (12.8) 141 (13.4) 0.96 (0.75-1.21) GFR <60 362 (24.5) 341 (23.7) 1.04 (.90-1.20) First morbid event 0.18 117 (11.4) 142 (13.5) 0.83 (0.65-1.06) 249 (16.9) 344 (23.9) 0.68 (0.60-0.80) First HF hospitalization GFR > 60 108 (10.5) 133 (12.6) 0.82 (0.64-1.06) 240 (16.3) 330 (22.9) 0.69 (0.55-0.81) Death or first morbid event 0.65 222 (21.6) 250 (23.7) 0.90 (0.75-1.08) 499 (33.8) 549 (38.1) 0.85 (0.76-0.96) *>60 vs <60 Anand IS. European Society of Cardiology Congress 2005; September 4-7, 2005; Stockholm, Sweden.